1 to 10 of 32
Sort by

Library Entry
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost...

Library Entry
SITC Webinar: I-O Highlights from ASCO 2019 - Recorded Webinar and Presentation Slides

On August 28, 2019, leading experts presented the latest advances in cancer immunotherapy emerging from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The webinar summarized key studies on the following topics: Biomarkers and checkpoint inhibitors Cellular therapies ...

2 attachments

Library Entry
Transgenerational transfer of gene-modified T cells

Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise including the long-term consequences of treatment among individuals of childbearing age....

Web Page
2019 WIN Leadership Institute

The Society for Immunotherapy of Cancer (SITC) is excited to announce the participants of the inaugural SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute, scheduled for Aug. 19-20, 2019, in Seattle, Wash. Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research...

Library Entry
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave of reports surfaced. With expanding I-O indications in the adjuvant/neoadjuvant...

Library Entry
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Human natural killer (NK) cell lines serve as an attractive source for adoptive immunotherapy, but NK-92 remains the only cell line being assessed in the clinic. Here, the authors established a novel NK cell line, NK101, from a patient with extra-nodal natural killer/T-cell lymphoma and examined...